These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24516020)

  • 1. Brivanib for hepatocellular carcinoma trials: selection bias from barcelona clinic liver cancer stage?
    Qi X; Jia J; Fan D; Han G
    J Clin Oncol; 2014 Mar; 32(9):968. PubMed ID: 24516020
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic therapy in HCC: lessons from brivanib.
    Bolos D; Finn RS
    J Hepatol; 2014 Oct; 61(4):947-50. PubMed ID: 24972045
    [No Abstract]   [Full Text] [Related]  

  • 3. Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
    Kelley RK
    J Clin Oncol; 2013 Oct; 31(28):3483-6. PubMed ID: 23980088
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to X. Qi et al.
    Llovet JM; Johnson PJ
    J Clin Oncol; 2014 Mar; 32(9):968-9. PubMed ID: 24516037
    [No Abstract]   [Full Text] [Related]  

  • 5. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
    Llovet JM; Decaens T; Raoul JL; Boucher E; Kudo M; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Bruix J; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; Ezzeddine R; Liu D; Walters I; Park JW
    J Clin Oncol; 2013 Oct; 31(28):3509-16. PubMed ID: 23980090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
    Johnson PJ; Qin S; Park JW; Poon RT; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Robles-Aviña J; Kudo M; Yan L; Sobhonslidsuk A; Komov D; Decaens T; Tak WY; Jeng LB; Liu D; Ezzeddine R; Walters I; Cheng AL
    J Clin Oncol; 2013 Oct; 31(28):3517-24. PubMed ID: 23980084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of intermediate-stage hepatocellular carcinoma.
    Finn RS
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):501-3. PubMed ID: 26351811
    [No Abstract]   [Full Text] [Related]  

  • 8. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
    Faivre S; de Gramont A; Raymond E
    Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune oncology in hepatocellular carcinoma-hype and hope.
    Wörns MA; Galle PR
    Lancet; 2017 Jun; 389(10088):2448-2449. PubMed ID: 28434649
    [No Abstract]   [Full Text] [Related]  

  • 10. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
    Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
    Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
    [No Abstract]   [Full Text] [Related]  

  • 11. Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?
    Bouattour M; Rousseau B; Wassermann J; Payancé A; Huillard O
    J Clin Oncol; 2015 Aug; 33(22):2484-5. PubMed ID: 26033820
    [No Abstract]   [Full Text] [Related]  

  • 12. Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors.
    Nault JC; Pigneur F; Nelson AC; Costentin C; Tselikas L; Katsahian S; Diao G; Laurent A; Mallat A; Duvoux C; Luciani A; Decaens T
    Dig Liver Dis; 2015 Oct; 47(10):869-76. PubMed ID: 26211871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
    Weintraub JL; Salem R
    J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma.
    Shen A; Tang C; Wang Y; Chen Y; Yan X; Zhang C; Liu R; Wei X; Zhu Y; Zhang H; Wu Z
    J Clin Gastroenterol; 2013; 47(10):871-80. PubMed ID: 24100749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of sorafenib in hepatocellular carcinoma.
    Gholam P
    Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
    [No Abstract]   [Full Text] [Related]  

  • 16. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Geschwind JF; Chapiro J
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to M. Bouattour et al.
    Cainap C; McKee MD; Ricker JL
    J Clin Oncol; 2015 Aug; 33(22):2486. PubMed ID: 26033815
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant sorafenib for liver cancer: wrong stage, wrong dose.
    Kelley RK
    Lancet Oncol; 2015 Oct; 16(13):1279-81. PubMed ID: 26433814
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter: Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients.
    Mancuso A; Zavaglia C; Bai F; Puoti M; Belli LS
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1414-6. PubMed ID: 24206381
    [No Abstract]   [Full Text] [Related]  

  • 20. Systemic therapy of hepatocellular carcinoma: current and promising.
    Kalyan A; Nimeiri H; Kulik L
    Clin Liver Dis; 2015 May; 19(2):421-32. PubMed ID: 25921671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.